Y-Intercept (HK)’s Celldex Therapeutics CLDX Stock Holding History

Y-Intercept (HK)’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2M	Sell	32,257 -12,935	-29%	-$418K	0.02%	964
2026 Q1	$1.43M	Buy	+45,192	New	+$1.23M	0.03%	883
2025 Q4	–	Sell	-48,906	Closed	-$1.27M	–	1601
2025 Q3	$1.27M	Sell	48,906 -9,492	-16%	-$220K	0.03%	861
2025 Q2	$1.19M	Buy	+58,398	New	+$1.14M	0.03%	856
2024 Q4	–	Sell	-30,538	Closed	-$1.04M	–	1246
2024 Q3	$1.04M	Buy	30,538 +3,146	+11%	+$120K	0.06%	435
2024 Q2	$1.01M	Buy	+27,392	New	+$1.03M	0.06%	487

Other funds holding CLDX

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $77B AUM 50.57% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $816M AUM 42.46% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return

Handelsbanken Fonder

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return